易明医药(002826) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was CNY 105,939,655.33, representing a 16.76% increase compared to CNY 90,734,178.49 in the same period last year[8] - Net profit attributable to shareholders was CNY 6,567,136.39, up 6.80% from CNY 6,148,774.24 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 5,628,563.52, reflecting an 11.75% increase from CNY 5,036,893.51 in the previous year[8] - The company reported a net profit margin improvement, with retained earnings rising to CNY 193,559,451.43 from CNY 186,992,315.04, an increase of approximately 3.0%[29] - The total profit for the current period was ¥7,772,562.59, up from ¥6,972,325.11, marking an increase of about 11.5%[37] - Operating profit for the current period was ¥7,300,145.44, slightly higher than ¥6,984,150.08 from the previous period, showing an increase of about 4.5%[37] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of CNY 7,265,933.10, a 66.26% reduction from CNY 21,537,556.18 in the same period last year[8] - The cash flow from operating activities showed a significant increase, with cash received from sales reaching ¥136,483,612.09, compared to ¥92,977,315.68 in the previous period[44] - The net cash flow from operating activities was -7,265,933.10 CNY, compared to -21,537,556.18 CNY in the previous period, indicating an improvement[45] - Total cash inflow from investment activities was 150,533,698.63 CNY, while cash outflow was 256,388,454.49 CNY, resulting in a net cash flow of -105,854,755.86 CNY[46] - Cash inflow from financing activities amounted to 70,000,000.00 CNY, with a net cash flow of 59,665,916.67 CNY after outflows[46] - The cash flow from operating activities showed a net outflow of -8,944,088.93 CNY, improving from -41,514,688.69 CNY in the prior period[49] Assets and Liabilities - Total assets at the end of the reporting period were CNY 800,042,545.77, a 5.56% increase from CNY 757,933,697.51 at the end of the previous year[8] - The net assets attributable to shareholders increased to CNY 625,047,947.99, up 1.07% from CNY 618,400,811.60 at the end of the last year[8] - Current liabilities rose to CNY 173,185,597.81, compared to CNY 137,661,135.93, indicating an increase of approximately 26%[28] - Short-term borrowings increased significantly to CNY 100,000,000.00 from CNY 40,000,000.00, marking a 150% rise[28] - Accounts payable increased by 47.64% to ¥16,571,732.06, mainly due to new unpaid invoices for products[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 22,007, indicating a stable shareholder base[12] - Basic and diluted earnings per share remained stable at CNY 0.03, unchanged from the same period last year[8] Government Support and Subsidies - The company received government subsidies amounting to CNY 568,250.01, primarily related to clinical trial approvals[9] - Other income decreased by 88.85% to ¥62,750.01, primarily due to a reduction in government subsidies received in the previous year[16] Research and Development - Research and development expenses decreased by 83.24% to ¥514,162.37, attributed to project progress[16] - Research and development expenses decreased significantly to ¥514,162.37 from ¥3,066,885.99, a reduction of approximately 83.3%[35] Investment Activities - Investment activities generated a net cash outflow of -¥105,854,755.86, a significant increase of 1336.07% compared to the previous year, due to payments for engineering and new short-term financial products[17] - The company has ongoing investments in fixed assets totaling CNY 190,302,868.36, slightly down from CNY 191,569,169.13[29] - Investment income for the current period was reported at ¥533,698.63, indicating a positive contribution to overall profitability[35] Operating Costs - Operating costs increased by 152.96% to ¥72,055,014.01, driven by revenue growth and changes in accounting methods due to the "two-invoice system" policy[16] - Total operating costs amounted to ¥99,235,958.53, up from ¥84,968,500.29, indicating an increase of about 16.8%[35]